MAGIC Cell-5-Combicytokine Trial

Seoul National University

Status and phase: Unknown; Phase 3; Phase 2

Conditions: Acute Myocardial Infarction

Treatments: Drug: G-CSF with/without darbepoetin, peripheral blood stem cell infusion

Study type: Interventional

Funder types: Other

Identifiers

NCT00501917

MAGIC Cell-5

Details and patient eligibility

About

Combination use of darbepoetin and G-CSF will improve left ventricular systolic function in patients with acute myocardial infarction who receive intracoronary infusion of mobilized peripheral blood stem cell in comparison with patient who treated with conventional measures and who received intracoronary infusion of mobilized peripheral blood stem cell by G-CSF alone.

Enrollment: 116 estimated patients

Sex: All

Ages: 15 to 80 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• ST elevation acute myocardial infarction
• < 80years
• successful revascularization of culprit vessel

Exclusion criteria

• uncontrolled congestive heart failure
• uncontrolled myocardial ischemia
• uncontrolled ventricular arrhythmia
• malignancy
• serious hematologic disease
• chronic renal failure

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Double Blind